Exicure

XCUR · NASDAQ

$0.9987−$0.0313 (−3.04%)TodayMarket closed · Oct 20, 7:07 PM ET

Prev close $1.03

About XCUR

Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The company is headquartered in Chicago, Illinois and currently employs 8 full-time employees. The company went IPO on 2018-05-09. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The firm is also exploring strategic alternatives to maximize stockholder value.

Employees: 8
Headquarters: Chicago, Illinois
Listed: May 9, 2018
Sector: Health Care
Industry: Biotechnology
Website: exicuretx.com

Leadership

Exicure executives
Name	Title	Since	Age
Jung Soo Kim	—	2026	53
Gyuyeob Lee	—	—	40
Josephine Cardarelli	—	—	—
Gyeung Seog Cheon	—	—	—
Jung Kyu Ham	—	—	—
Dongho Lee	—	—	63
Sangjn Yeo	—	—	54

Similar companies

Companies in the same industry as Exicure

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.